Details, Fiction and Ponsegromab
All enrolled people who obtained at least one particular dose of zosuquidar or placebo throughout induction have been monitored for the event of adverse functions (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions were connected to the duration of extended and sizeable myelosuppression as is expected with induction